Clinical Trails

Results from a Phase 2a trial suggest that adding atebimetinib to modified gemcitabine and nab-paclitaxel (mGnP) chemotherapy may improve outcomes for patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Atebimetinib is a novel MEK inhibitor designed with a short half-life, allowing it to temporarily block cancer-growth signaling while reducing the toxicities and resistance often seen […]

Results from the Phase 3 OptimUM-02 trial show that the combination of darovasertib and crizotinib significantly improves outcomes for patients with HLA-A*02:01–negative metastatic uveal melanoma, a rare and aggressive form of eye cancer with no approved treatment options for this population. The targeted therapy works by blocking the PKC signaling pathway, which is activated in more

A small clinical trial led by researchers at the Dana-Farber Cancer Institute suggests that a vitamin D analog may help improve treatment outcomes in pancreatic cancer. The study tested paricalcitol, an FDA-approved drug used for kidney disease, in combination with standard chemotherapy for 36 patients with previously untreated metastatic pancreatic cancer. Researchers found that paricalcitol

The phase 3 PEAK trial showed that combining bezuclastinib, a selective oral KIT inhibitor, with sunitinib significantly improves outcomes in patients with advanced gastrointestinal stromal tumors (GIST) who have progressed after first-line therapy. The combination reduced the risk of disease progression or death by 50%, with median progression-free survival of 16.5 months versus 9.2 months

The Phase 1/2a BLUESTAR trial showed promising results for puxitatug samrotecan (Puxi-Sam), a B7-H4-targeting antibody-drug conjugate developed for advanced gynecologic cancers. The drug delivers a topoisomerase 1 inhibitor directly to tumor cells expressing B7-H4, a protein commonly found in endometrial and ovarian cancers. At the recommended 2.4 mg/kg dose, Puxi-Sam achieved an objective response rate

The phase 1 NEXUS-01 trial demonstrated encouraging activity for LY4052031, a next-generation Nectin-4-targeting antibody-drug conjugate (ADC) for metastatic urothelial carcinoma. Designed to overcome resistance to enfortumab vedotin (EV), LY4052031 uses a novel topoisomerase 1 inhibitor payload. Among heavily pretreated patients previously exposed to EV, the drug achieved an objective response rate (ORR) of 33% and

The phase 3 SUCCESSOR-2 trial showed that adding mezigdomide, an oral CELMoD, to carfilzomib and dexamethasone significantly improved outcomes for patients with relapsed or refractory multiple myeloma. The triplet regimen doubled median progression-free survival to 18.0 months compared with 8.3 months for carfilzomib and dexamethasone alone, reducing the risk of disease progression or death by

A Phase 1 trial of RD118, a novel fully human anti-GPRC5D CAR T-cell therapy, showed strong and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma. The study enrolled 18 patients, many with high-risk disease, including prior BCMA CAR T failure. With a median follow-up of 17 months, the overall response rate

Early results from the phase 2 CONVERGE trial show that JNJ-1900 can be safely combined with standard concurrent chemoradiotherapy for patients with stage 3 unresectable non–small cell lung cancer. JNJ-1900 is a nanoparticle-based radioenhancer injected directly into tumors or lymph nodes before radiation treatment. Investigators reported that the injection procedure was feasible and did not

A phase 1b/2 trial showed promising results for a new combination therapy in patients with HER2-positive metastatic breast cancer who had already failed treatment with Enhertu. The study evaluated zanidatamab-hrii, a HER2-targeted bispecific antibody, together with evorpacept, a CD47 blocker, in 24 heavily pretreated patients. Overall, the response rate was 33.3%, but patients with centrally